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Abstract
Streptococcus suis is a major porcine pathogen of significant commercial importance worldwide and an emerging zoonotic
pathogen of humans. Given the important sentinel role of mucosal dendritic cells and their importance in induction of T cell
responses we investigated the effect of different S. suis serotype strains and an isogenic capsule mutant of serotype 2 on the
maturation, activation and expression of IL-10, IL-12p70 and TNF-a in human monocyte-derived dendritic cells. Additionally,
we compared phagocytosis levels and bacterial survival after internalization. The capsule of serotype 2, the most common
serotype associated with infection in humans and pigs, was highly anti-phagocytic and modulated the IL-10/IL-12 and IL-10/
TNF-a cytokine production in favor of a more anti-inflammatory profile compared to other serotypes. This may have
consequences for the induction of effective immunity to S. suis serotype 2 in humans. A shielding effect of the capsule on
innate Toll-like receptor signaling was also demonstrated. Furthermore, we showed that 24 h after phagocytosis, significant
numbers of viable intracellular S. suis were still present intracellularly. This may contribute to the dissemination of S. suis in
the body.
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Introduction
Streptococcus suis is a major pathogen of swine, causing
considerable economic losses and animal health care problems
for the pig farming industry worldwide [1]. The natural habitat of
S. suis is the upper respiratory tract and the intestinal tract [2,3]. In
adult pigs carriage of S. suis is usually asymptomatic but colonized
sows can infect their piglets after nasal or oral contact [4].
Newborn pigs can also become infected during parturition when
they contact, swallow or aspirate S. suis from sow vaginal secretions
[5]. In young pigs S. suis infection causes a wide variety of diseases,
including meningitis, septicemia which are the main causes of
mortality. S. suis is also emerging as a serious zoonotic pathogen of
humans particularly in South East and East Asia where it is one of
the most common causes of human meningitis [6,7]. In 2005 a
large outbreak of 215 cases S. suis infections occurred in Sichuan,
China, resulting in 38 deaths [8]. There are 33 serotypes of S. suis
of which serotype 2 is most commonly associated with disease in
humans and pigs worldwide [9,10]. In addition serotypes 1 to 9
and 14 are responsible for infections in pigs [11] and serotypes 1,
4, 5, 14, 16 and 24 have caused severe disease in a limited number
of persons [12,13,14,15]. The capsule is known to be a very
important virulence factor in S. suis [16]although not all capsulated
isolates (including serotype 2) are virulent, highlighting the
importance of other virulence factors in the pathogenesis of
disease [3].
Dendritic cells (DCs) are important sentinels in the skin and
mucosal surfaces that contact the external environment and play a
key role in the homoeostatic control tolerance and immunity in the
mucosal tissues [17]. Stromal factors such as retinoic acid and
thymic stromal lymphopoietin imprint tolerogenic properties on
resident DC. However when invading microbes are encountered
the homeostatic mechanism are overridden by chemotactic
recruitment of DC and their activation by pattern recognition
receptor (PRR) binding to pathogen-associated molecular patterns
(PAMPs). Upon activation DCs express up to 100x more MHC
than monocytes, macrophages and neutrophils other antigen
presenting cells (APCs) and migrate to mucosal associated
lymphoid tissue to induce antigen-specific T cell responses
[18,19]. Thus DCs are instrumental in the orchestration of
adaptive immune responses. Cytokines produced by activated DC
have a major influence on T cell polarization, differentiation and
clonal expansion. Interleukin (IL)-12 and tumor necrosis factor
(TNF)-a, are pro-inflammatory cytokines that promote T helper
(Th) 1 cell responses, whereas IL-10 is an anti-inflammatory
cytokine that can promote induction of Th2 cells or regulatory T
cells depending on the expression of other tolerizing factors [20].
DCs recognize different types of PAMPs using pattern
recognition receptors (PRRs) of the Toll-like receptor (TLR),
nucleotide-binding oligomerisation domain receptor (NLR) and C-
type lectin receptor (CLR) protein families, [17,21,22]. PRR
signaling is critical to DC maturation and in recent years much
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pathways involved in pathogen recognition. Each PRR recognizes
variants of a specific molecular pattern and can be expressed on
the cell surface, in intracellular compartments or in the cytosol.
TLR1, 2, 4, 5, 6 and 11 recognize mainly microbial envelope
components and are expressed on the cell surface, TLR3, 7, 8 and
9 recognize microbial nucleic acids and are expressed in
intracellular compartments such as the endoplasmic reticulum,
endosome and phagosome. TLR2 can form heterodimers with
TLR1 or TLR6 to detect different, but related ligands. TLR2/1
recognizes tri-acyl lipoproteins found predominantly in Gram-
negative bacteria and TLR2/6 the diacyl groups on lipoteichoic
acid and lipoproteins of Gram-positive bacteria. NOD1 and
NOD2 are cytoplasmic receptors that can detect peptidoglycan
fragments produced in the phagosome or phagolysosome of
antigen presenting cells although the nature of the transporters
involved in translocation to the cytoplasm remains unknown [23].
The CLR family is characterized by the presence of one or more
C-type lectin-like domains (CTLDs) and bind mainly sugars
including self-antigens. CLRs trigger distinct signaling pathways
that induce the expression of specific cytokines which determine T
cell polarization fates [24].
Recently the interactions of a virulent serotype 2 strain and its
unencapsulated derivative with porcine DC were studied in vitro.
The capsular polysaccharide was shown to interfere with
phagocytosis and consequently the level of DC maturation and
production of several cytokines was reduced compared to an
unencapsulated strain [25]. Given the emergence of S. suis as a
significant cause of meningitis in humans we investigated the effect
of different serotypes (SS1, SS2, SS4, SS7, SS9 and SS14) and the
unencapsulated mutant of S. suis serotype 2 (SS2 J28) on the
maturation and expression of IL-10, IL-12p70 TNF-a in human
monocyte-derived DC. Additionally, we compared the efficiency
of the different isolates in DC phagocytosis assays and studied the
intracellular survival of internalized S. suis serotype 2of internal-
ized S. suis serotype 2 S10 and its unencapsulated isogenic mutant.
The ability of the different serotype strains to induce TLR
signaling via human TLR2/6 was also investigated using a TLR2/
6 specific luciferase reporter cell line. To our knowledge this is the
first study concerning the interactions of S. suis with human DC
and it provides new knowledge of the role of different capsular
polysaccharide serotypes in the avoidance of host innate
immunity.
Materials and Methods
Bacterial strains
Six different serotypes (SS1, SS2, SS4, SS7, SS9 and SS14) and
the unencapsulated mutant of SS2 (SS2 J28) were obtained from
Central Veterinary Institute, Lelystad NL (Table 1). In table 1 for
each strain the expression of three virulence markers are indicated:
two secreted cell wall located proteins namely the muramidase-
released protein (MRP) and the extracellular factor (EF) [26,27],
and secreted hemolytic toxin suilysin (SLY) [28]. MRP and EF
variants have been designated as MRP
S and EF*. All S. suis strains
were cultured overnight at 37uC in Todd Hewitt broth (Oxoid).
The bacteria were then recovered by centrifugation, washed twice
in phosphate buffered saline (PBS, pH=7.4), resuspended at
approximately 1610
9 colony forming units (CFU)/mL in PBS
containing 20% glycerol, and stored in aliquots at 280uC prior to
use. The exact number of bacterial CFU in a thawed aliquot was
determined by plating serial dilutions on Columbia blood agar
plates (BD) containing 5% sheep blood in presence of 5% CO2.
Differentiation and maturation of dendritic cells
The study was approved by the Wageningen University Ethical
Committee and was performed according to the principles of the
Declaration of Helsinki. Buffy coats from four blood donors were
obtained from the Sanquin Blood bank Nijmegen, Netherlands. A
written informed consent was obtained before the sample
collection. Human monocytes were isolated from blood using a
combination of Ficoll density centrifugation and cell separation
using CD14-specific antibody coated magnetic microbeads
(Miltenyi Biotec). The purity of isolated CD14+ cell fraction was
greater than 90% and viability .95% in all experiments. To
generate immature DC (iDCs), the purified CD14+ cells were
cultured for 6 days in RPMI 1640 medium (Invitrogen),
supplemented with 100 units/mL penicillin G (Invitrogen),
100 mg/mL streptomycin (Invitrogen), IL-4 (R&D systems) and
granulocyte-macrophage colony-stimulating-factor (GM-CSF)
(R&D systems). GM-CSF and IL-4 were added to differentiate
the monocytes into myeloid DCs. At day 6 the iDCs (1610
6 /mL)
were stimulated with LPS (1 mg/mL) or the different S. suis
serotypes at multiplicities of infection (MOI) of 1 bacterium per
DC or 10 bacteria per DC for 48 hours. Unstimulated iDCs were
used as a negative control.
Table 1. List of strains used in this study.
Serotype Strain Virulence for pigs MRP EF Suilysin CPS Reference
SS1 6388 HV MRP
s EF
+ SLY
+ Cps1
+ [47,48]
SS2 S10 V MRP
+ EF
+ SLY
+ Cps2
+ [16]
SS2 J28 10cpsDEF
a AV MRP
+ EF
+ SLY
+ Cps2
2 [16]
SS4 5213 ND MRP
s – ND Cps4
+ [49]
SS7 8039 ND – – – Cps7
+ [48,50]
SS9 8067 AV – – SLY
+ Cps9
+ [48,51]
SS14 13730 ND – EF* ND Cps14
+ –
aThe isogenic unencapsulated mutant strain 10 cpsDEF parts of the cps2E and cps2F gene were replaced by an antibiotic resistance gene. HV high virulent V virulent AV
avirulent. MRP muraminidase-released protein. EF extracellular factor. SLY suilysin. CPS capsular polysaccharide synthesis *, higher MW protein expressed; s, smaller MW
protein expressed.
doi:10.1371/journal.pone.0035849.t001
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death by flow cytometry
During the 8 day culture period of the CD14+ cells (6 days of
differentiation of monocytes into immature dendritic cells and two
days of stimulation), cells were stained on days 3, 6 and 8 with
fluorescence-conjugated monoclonal antibodies specific for CD83,
CD86 or their isotype-matched controls (BD biosciences, San
Diego, USA) and analyzed by flow cytometry (FACSCanto II, BD,
San Diego, USA) to check the maturation and activation status of
the cells. CD86 and CD83 were not expressed on immature
dendritic cells (d 3 and 6) but were highly expressed on DCs after
activation with known maturation factors (e.g. LPS). The
magnitude of the response from different human donors can vary
considerably so for comparison the data was normalized to the
LPS control sample data (100%) for each donor.
On days 3, 6 and 8 the percentage of viable cells was measured
by flow cytometry (FACSCanto II, BD, San Diego, USA). Live,
apoptotic and necrotic cells were discriminated by staining with
Annexin V and propidium iodide on days 3, 6 and 8 according to
the manufacturer’s protocol. The cells were analyzed on a flow
cytometer (FACSCanto II, BD, San Diego, USA). Cells that are
negative for both Annexin V and PI are not apoptotic or necrotic
as translocation of the membrane phospholipid phosphatidylserine
has not occurred and the plasma membrane is still intact.
Therefore, Annexin V and PI double negative cells were
considered as viable cells, whereas both single and double positive
cells were regarded as non-viable [29]. The flow cytometry data
was analyzed using the BD FACSDiva software. On days 3 to 8
the viability of the cells was between 60 and 95%. There were no
significant differences in cell death between S. suis co-cultures or
compared to the medium and LPS controls.
Cytokine assay
Supernatants from the DC stimulation assays were collected
after stimulation for 48 hours, and analyzed for the presence of
cytokines (IL-10, IL-12p70 and TNF-a) using a cytometric bead-
based immunoassay that enables multiplex measurements of
soluble cytokines in the same sample [30], according to the
manufacturer’s protocol (BD biosciences). The limits of sensitivity
for detection were as follows: 0.13 pg/mL, 0.6 pg/mL and
0.7 pg/mL. The flow cytometry data were analyzed using the
BD FCAP software.
Phagocytosis assay
The iDCs (10
6 cells) were inoculated with the different S. suis
serotypes (MOI 10) and incubated for one hour in antibiotic-free
RPMI 1640 at 37uC and the presence of 5% CO2. The DCs were
further incubated for one hour in RPMI 1640 containing
56.2 mg/mL penicillin G and 100 mg/mL gentamicin. Subse-
quently the DCs were collected and the centrifuged for 5 minutes
at 845 g. The pellet was washed with PBS to remove the
antibiotics and the DCs lysed and vigorously vortex in ice-cold
milliQ water. The cell lysate was then serial plated on Columbia
blood agar plates (BD) containing 5% sheep blood to enumerate
the CFU of S. suis.
Adhesion and Phagocytosis Assay. The iDCs (10
6 cells)
were inoculated with SS2 and SS2 J28 (MOI10) and incubated for
1 hour in antibiotic-free RPMI1640. To count the adherent and
phagocytosed bacteria DCs were washed after one hour twice with
PBS to remove the unbound bacteria, lysed with ice-cold milliQ
water and plated on Columbia blood agar plates (BD) containing
5% sheep blood.
Kill Curve
Phagocytosis of S. suis was performed as described above and
then the DCs were incubated in RPMI 1640 containing 56.2 mg/
mL penicillin G and 100 mg/mL gentamicin to kill extracellular
bacteria. The killing of phagocytosed S. suis was determined after
1, 2, 3 and 4 h by removing the antibiotics with PBS washes, lysis
in ice-cold milliQ water and serial plating on Columbia blood agar
plates (BD) containing 5% sheep blood.
Survival of S. suis inside DCs after 2 and 24 hours
The iDCs (10
6 cells) were inoculated with SS2 and SS2 J28
(MOI10) and incubated for one hour in antibiotic-free RPMI1640.
After one hour of incubation antibiotics (100 mg/mL gentamicin and
56.2 mg/mL of penicillin G) were added to kill all the extracellular
bacteria. After a further one hour incubation in the presence of the
antibiotics DCs samples were collected and plated in the same way as
described in the phagocytosis assay (2 h time point). After a further
4 hours, the medium was replaced by RPMI lacking antibiotics to
prevent the antibiotics from entering the DCs and killing intracellular
bacteria. After a total of 23 hours incubation the DCs were incubated
for one hour in RPMI with or without antibiotics washed twice with
PBS, lysed with ice-cold milliQ water and plated on Columbia blood
agar plates (BD) containing 5% sheep blood (24 h time point).
TLR2/6 assay
The TLR2/6 signaling assay was performed essentially as
previously described [31]. Briefly, HEK293 cells (Invivogen,
Toulouse, France) were transformed with human TLR2/6 and
pNIFTY, a NF-kB luciferase reporter construct (Invivogen). The
cells were plated a concentration of 6610
4 cells per well in
DMEM medium. Cells were then stimulated with the different S.
suis strains, Pam2CSK as a positive control and with medium
alone (negative control) and incubated at 37uC and 5% CO2 for
24 hours. After this incubation period the medium was replaced
with Bright glow (Promega), the plate was vortexed and the
luminescence was measured using a Spectramax M5 (Molecular
Devices). Human embryonic kidney (HEK)293 cells not expressing
TLR receptors but harbouring pNIFTY, a NF-kB luciferase
reporter construct (Invivogen, Toulouse, France) were used as the
negative control in the NF-kB assays.
Electron microscopy
For morphological analysis of the capsule structure, samples of
exponential phase (,0.5 OD600) bacteria were fixed according to
the lysine-acetate-based formaldehyde/glutaraldehyde ruthenium
red-osmium (LRR) fixation procedure, as described previously
[32] and studied by JEOL JEM 2100 transmission electron
microscope at magnifications of 25.000 X.
Statistical analysis
Dixon’s Q test was applied for the evaluation of differences in the
values of the immune- and cytokine assays. Datasets contained values
of six different donors. P values of ,0.05 were considered significant.
Independent sample t-test was applied for the evaluation of
differences between SS2 and SS2J28 in the phagocytosis assay and
the kill curve. P,0.05 were considered significant.
Results
S. suis capsule serotype differentially affects DC
maturation and activation
Immature monocyte-derived DCs derived from six different
human donors were used as in vitro model to investigate
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35849Figure 1. Mean Fluorescence Intensity (MFI) of dendritic cells normalized with LPS. The MFI of stained cell surface markers by monocyte
derived dendritic cells with 6 different S. suis strains and SS2J28 mutant, with immature DCs as the negative control and LPS as the positive control.
A. MFI of CD83 B. MFI of CD86. Bars showing unequal letters significantly differ in their surface marker expression (P,0.05). C. Histograms for
expression of surface markers CD83 and CD86. Dotted lines represent the isotype controls and black lines the stimulated samples. In case of bacteria
a black line represents a MOI 1 and a dashed line a MOI 10.
doi:10.1371/journal.pone.0035849.g001
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with 6 different S. suis serotypes and SS2J28 at MOI 1 and MOI
10 (Fig. 1). Expression of the surface expressed co-stimulatory
molecule CD86 and maturation marker CD83 were measured to
determine the activation and maturation status of the DCs
respectively (Fig. 1A and B for mean fluorescence intensity and 1C
for histograms). For all encapsulated strains stimulation of DC
with S. suis at a MOI 10 resulted in higher maturation and
activation marker expression than at MOI 1. The induction of the
surface expression CD86 and CD83 differed markedly among the
capsule serotypes tested. Significantly higher levels of CD83 and
CD86 were observed following DC stimulation with serotypes
SS1, SS7 and SS9 and the unencapsulated SS2 mutant than with
serotype SS2. Interestingly, serotype SS2 was the least effective at
maturating DC although its unencapsulated variant, SS2J28 was
the most effective indicating the importance of the capsule in the
avoidance of host innate immunity.
The capsule of S. suis serotype 2 differentially modulates
the IL-10 to IL-12 ratio
The amounts of IL-10, IL-12 and TNF-a measured in the
supernatants of DC co-cultured with the different serotypes was
highly variable (Fig. 2). The amounts of IL-10 ranged from 5 pg/
mL to 56 pg/mL, IL-12p70 from 7 pg/mL to 6948 pg/mL and
TNF-a from 5 pg/mL to 3744 pg/mL (Fig. 2A–C). As expected,
stimulation with an MOI 10 resulted in higher amounts of secreted
cytokine than stimulation with an MOI 1. In keeping with the data
on maturation markers (Fig. 1) serotypes SS1, SS7 and SS9 were
the highest inducers of cytokines, whereas serotype SS2 induced
the lowest amounts of cytokines (all cytokine ,10 pg/mL). In
contrast the unencapsulated derivative SS2J28 stimulated the
highest amounts of IL-10 and IL-12 and high amounts of TNF-a.
The ratio of IL-10 to IL-12 is often used as an indicator of the
potential to polarize T cell responses towards Th1 or Th2/Treg
[17]. Interestingly all of the S suis serotypes except SS2 induce low
IL-10 to IL12 ratios (less than 0.08). For SS2 the IL-10 to IL-12
ratio was 0.34 at MOI 10 and almost 1.0 (0.98) at MOI 1.
Strikingly, the unencapsulated derivative of SS2 designated
SS2J28 has a much lower IL-10 to IL-12 ratio than SS2 (0.03 at
MOI 1 and 0.008 at MOI 10) suggesting that the type 2 capsule
can down-regulate the host cell-mediated response to S. suis
(Fig. 2D). Similar trend of ratio’s were observed for the IL-10 to
TNF-a ratio (Fig. 2E).
Effect of capsular polysaccharide on the capacity of DCs
to internalize S. suis
The percentage of S. suis phagocytosed by DCs varied
considerably among the different serotypes tested. After one hour
of incubation of the DCs with the bacteria, SS4 and SS9 were
more efficiently taken up by the DCs (respectively 23% and 20%
of original inoculum (10
7 bacteria) compared to the other strains
(Fig. 3). In contrast capsule types SS1 and SS2 were relatively
resistant to phagocytosis by DCs (0.04% and 2.16% respectively
the original inoculum). The unencapsulated mutant was internal-
ized at significantly higher amounts than its wild type SS2
progenitor (5.29% vs 2.16%; P=0.0001). Surprisingly however,
the unencapsulated strain was less efficiently internalized than
serotype strains SS4 and SS9 (Fig. 3).
Figure 2. Cytokine secretion by dendritic cells. Cytokine production by monocyte derived dendritic cells with 6 different S. suis strains and
SS2J28, with immature DCs as the negative control and LPS as the positive control. A. IL-10 B. IL-12p70 C. TNF-a. D. IL-10/IL-12 ratio. E. IL-10/TNF-a.
doi:10.1371/journal.pone.0035849.g002
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internalized S. suis
To rule out the possibility that differences in internalization of
SS2 and SSJ28 by DC might be due to strain variation in
intracellular survival we measured the survival of these two strains
in DC over time. After one hour of incubation with iDC
antibiotics were added for 1 hour to ensure that only internalized
bacteria were counted after lysis of the DCs. After a total 2 hours
of incubation the number of viable bacteria inside the DCs
decreased considerably, to 39% of the original inoculum for SS2
and 43% of the inoculum for SS2J28 (Fig. 4A). Over the first
4 hours the number of viable S. suis decreased at a similar rate for
both strains indicating that the higher level of internalization
measured for SS2 J28 (Fig. 4A) could not be due to less rapid
killing.
Viable S. suis reside within DC 24 hours after
phagocytosis
To examine the survival of the wild type SS2 and its mutant
SS2J28 inside the DCs after 24 hours, the DCs (10
6 cells) and
bacteria (MOI 10) were incubated for 2 and 24 hours (Fig. 4B).
After 1 hour of incubation antibiotics were added to the medium
kill extracellular and adhered bacteria. After 5 hours, the medium
was replaced by RPMI without antibiotics, to prevent the
antibiotics from entering the DCs. After 24 hours around
10
3 CFU/mL of live S. suis were recovered from the lysed DC
suggesting that a small proportion of the bacteria could survive
intracellularly. To rule out that these phagocytosed bacteria were
released from DC after 5 hours of co-incubation and were
growing in the medium the experiment was repeated using an
additional antibiotic treatment at 23 hours to kill any extracellu-
lar/adherent bacteria that might be present. The results (Fig. 4B)
showed that the CFU/mL counts present after 24 hour could be
attributed to the presence of intracellular S. suis.
Involvement of TLR2 and TLR6 in innate immune
signaling by S. suis
TLR2/6- mediated activation of NF-kB could be one of the
major pathways for DC activation via LTA or lipoproteins in the
cell envelope of S. suis. Therefore we tested the TLR2/6 signaling
capacities of all the serotypes in a reporter assay using HEK293
cells expressing human TLR2 and TLR6 heterodimer that
recognizes lipoteichoic acid (LTA) and lipoprotein lipid anchors
in Gram-positive bacteria (Fig. 5). HEK293 cells transformed with
only the pNIFTY, a NF-kB luciferase reporter construct did not
respond to Pam2CSK demonstrating the dependency of NF-kB
activation on co-expression of hTLR2/6 receptor. Medium was
used as a negative control and Pam2CSK (synthetic agonist of
TLR2/6) as a positive control. The results shown in Fig 5
demonstrate that indeed all strains are capable of triggering NF-
kB activation via TLR2/6 signaling but there was no correlation
between the capacity of the strains to induce TLR2/6 signaling
and activate DC (Fig. 2). Interestingly the unencapsulated mutant
of SS2 induced significantly (P,0.05) higher levels of NF-kB than
SS2 indicating that the capsule has a shielding effect on TLR
activation.
Morphological analysis of SS2 and SS2J28
For morphological analysis of the capsule structure, samples of
exponential phase (,0.5 OD600) SS2 and SS2J28 were studied by
electron microscope at magnifications of 25.000 X. As expected
SS2 showed a thick capsule whereas no capsular material can be
observed in the isogenic mutant strain SS2J28 (Fig. 6).
Figure 3. Phagocytosis assay. Phagocytosis by immature DCs with 6
different S. suis strains and an unencapsulated mutant at an MOI 10.
This is a representative figure from 1 donor, out of 5 donors. *P,0.05.
doi:10.1371/journal.pone.0035849.g003
Figure 4. Survival of S. suis inside dendritic cells. A. Kinetics of
adhesion and phagocytosis Immature DCs were inoculated with SS2 and
SS2 J28 at a MOI of 10 bacteria/DC for subsequently 2, 3, 4, 5 and
24 hours of incubation. B. Survival of S. suis inside DCs after 2 and
24 hours Immature DCs were inoculated with SS2 and SS2J28 at a
MOI10 for 2 and 24 hours of incubation. The last hour the DCs were
incubated with (24+) or without (24) antibiotics.
doi:10.1371/journal.pone.0035849.g004
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Apart from its major economic impact on the mortality and
morbidity of young pigs in agro-food production S. suis is emerging
as a one of the major causes of meningitis in South East Asia. To
gain further knowledge on the role of S. suis capsule and capsule
serotype on the immune response of the human host we compared
phagocytosis and immune responses of human immature DC to
different serotypes of S. suis. DCs are professional antigen
presenting cells that play a key role in the induction of adaptive
immune responses. Once activated by contact with invading
pathogens CD103
+ DC can traffic from the sites of mucosal
infection to the draining lymph nodes to induce T cell responses.
Additionally they play a crucial role in induction of adaptive
immune responses in the Peyer’s patches of the nasal mucosa and
small intestine. Many pathogens have evolved mechanisms to
avoid phagocytosis including production of leukotoxins, the
inhibition of complement activation and masking of binding sites
for endocytic receptors by polysaccharide capsules [33].
The serotypes of S. suis differed significantly in their ability to
activate DCs and induce cytokine responses. Serotypes SS1, SS7
and SS9 induced expression of significantly higher levels of DC
activation and maturation markers than serotypes SS2, SS4 and
SS14 (Fig. 1). Interestingly SS2, the strain that was the least
effective at activating and maturating DC was serotype 2, which is
the serotype most commonly associated with invasive disease in
pigs and humans [34]. In contrast the unencapsulated variant of
SS2 (SS2J28) was the most effective strain in maturating and
activating DC, indicating the important role of the capsule in
shielding cell wall components that activate DC and induce
cytokine responses (Fig. 1). The thickness of the capsule may also
influence the activation by influencing the release of MAMPs such
as lipoproteins and LTA. Capsule serotype 1 has been reported to
have a thinner capsule than other serotypes [51] and interestingly
this was the most effective of all capsulated strains in activating and
maturating DC. The anti-phagocytic effects of SS2 capsule were
apparent from the significantly higher phagocytosis of the
unencapsulated mutant SS2J28 (5.29% vs 2.16%; P=0.0001)
(Fig. 3). To rule out the possibility that differences in internali-
zation of SS2 and SS2J28 by DC might be due to strain variation
in intracellular survival we measured survival over period of
4 hours after phagocytosis. The number of viable S. suis decreased
at a similar rate for both strains indicating that the higher level of
internalization measured for the unencapsulated mutant SS2J28
(Fig. 3) was not due to less rapid killing (Fig. 4A). Similar results
were recently described using porcine DCs and a capsulated and
unencapsulated serotype 2 strain [25]. As in our own study an
unencapsulated mutant of a serotype 2 strain was phagocytosed at
significantly higher levels and once internalized, both the wild-type
strain and its non-encapsulated mutant were killed at similar rates.
To investigate the effect of other capsule types on phagocytosis
the internalization of several other serotypes were compared to
serotype 2 and its unencapsulated mutant SS2J28 (Fig. 3). The
serotypes differed considerably in their ability to be phagocytosed
with around 20% of the inoculum being internalized in the case of
SS4 and SS9 but only 2% in the case of SS2 (Fig. 3). This might be
explained by the difference in composition of the capsulesand their
charge which is known to be important in the avoidance of
phagocytosis. A recent genetic analysis of the capsular polysac-
charide synthesis locus of 15 S. suis serotypes predicted that
capsules of serotypes 1, 2, and 14 may contain sialic acid [35]. In
Streptococcus agalactiae capsule sialic acid has been shown to increase
the hydrophilic surface properties of the bacteria and have an
inhibitory effect on phagocytosis [36]. This might be an
explanation for the fact that phagocytosis of serotype strains 1, 2
and 14 was significantly lower than for serotype strains 4 and 9.
The sialylated capsule of Streptococcus agalactiae also inhibits C3
deposition on the bacterial cell surface [37], probably via
recruitment of factor H, an anti-activator of the complement
alternative pathway [38]. However it is not evident that C3
deposition is inhibited by sialic acid in the serotype 2 capsule of S.
Figure 5. hTLR2/6 assay. HEK293 cells were incubated with 6
different S. suis strains and an unencapsulated mutant at a MOI10,
PAM2CSK as a positive control and medium as a negative control. This
figure is representative out of three hTLR2/6 assays. *P,0.05.
doi:10.1371/journal.pone.0035849.g005
Figure 6. Detection of encapsulation of S. suis strains by LRR staining and transmission electron microscopy. S. suis 2 strain 10 shows a
thick capsule, whereas no capsular material can be seen in isogenic mutant strain S. suis 21 0 DcpsEF.
doi:10.1371/journal.pone.0035849.g006
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presence or absence of serum factors [25].
Interestingly the unencapsulated SS2J28 strain was less
efficiently phagocytosed than serotype strains SS4 and SS9
(Fig. 3). Thus it is possible that SS2 has other mechanisms that
inhibit phagocytosis. A two-component regulatory system (TCS)
designated SalK/SalR has been shown to have a protective role in
the killing of S. suis by granulocytes [16,39,40] but this locus is
absent in the genome of SS2 strain and thus cannot be responsible
for the lower levels of phagocytosis observed for SS2 compared to
SS4, SS7, SS9 and SS14.
A shielding effect of SS2 capsule was investigated using a
reporter cell line for TLR2/6 signaling. The TLR2/6 heterodimer
is formed by binding of the di-acyl groups present on lipoproteins
of Gram-positive bacteria and lipoteichoic acids present in the cell
wall [22,41]. This triggers NF-kB activation via a signal kinase
cascade involving the adapter protein MyD88 and was detected in
our assay by production of luciferase under control of an NF-kB
promoter. The unencapsulated mutant of SS2 induced signifi-
cantly (P,0.05) higher levels of NF-kB than SS2 suggesting that
the capsule has a shielding effect on the exposure of TLR agonists
that can activate DCs (Fig. 5). Notably, the level of NF-kB
activation obtained with the unencapsulated mutant was signifi-
cantly lower than for SS9 (P,0.0001), SS14 (P,0.0001) and SS4
(P,0.0001). The highest level of TLR2/6 activation was observed
for SS9, something observed in a previous study using the same
strains SS2 and SS9 (Fig. 5) [42]. Interestingly we found that SS9
was phagocytized more efficiently than the other strains and was
highly effective at activating DC. However efficiency of phagocy-
tosis did not correlate with activation of DC as evident for strain
SS1 which was phagocytized at relatively low levels compared to
the other serotypes but nevertheless strongly activated DC in co-
culture.
The amounts of IL-10, IL-12, and TNF-a measured in the
supernatants of DC co-cultured with the different serotypes was
highly variable (Fig. 2). The amounts of IL-10 ranged from 5 pg/
mL to 56 pg/mL, IL-12p70 from 7 pg/mL to 6948 pg/mL and
TNF-a from 5 pg/mL to 3744 pg/mL (Fig. 2A–C). In agreement
with the data on maturation and activation markers (Fig. 1) the
serotypes SS1, SS7 and SS9 were the highest inducers of cytokines,
whereas serotype SS2 induced the lowest amounts of cytokines (all
cytokine ,10 pg/mL). Interestingly all of the S suis serotypes
except SS2 induce low ratios of IL-10 to IL12 ratios (less than
0.08). For SS2 the IL-10 to IL-12 ratio was 0.34 at MOI 1 and
almost 1.0 (0.98) at MOI 10. This qualitative effect on the cytokine
response was due to the serotype 2 capsule because the
unencapsulated mutant of SS2 induced cytokines with a low IL-
10 to IL-12 ratio (0.03 at MOI 1 and 0.008 at MOI 10) as
observed for the other serotypes (Fig. 2D). A similar trend was seen
for the IL-10/TNF-a cytokine ratio (Fig. 2E). Although induced
levels of IL-10 were relatively low for both strains the
unencapsulated mutant induced more than 100 fold higher levels
of the pro-inflammatory IL-12 and TNF-a than the capsulated
strain. It is not known whether the immunomodulatory effect of
SS2 capsule is also observed with porcine DC as the recent study
did not measure IL-10 production by DC [25]. A consequence of
increased IL-10 production may be the polarization of T helper
cell responses towards Th2 or Treg [43]. In pathogenic species of
Yersinia for example, the secreted V antigen protein induces IL-10
in macrophages to evade the host’s inflammatory response during
infection [44]. Pathogens such as Mycobacterium tuberculosis and HIV
target DC-SIGN on DC to escape immunity. Binding to DC-
SIGN cause internalization but not subsequent antigen processing
and induces IL-10 expression resulting in suppression of Th1
responses [45]. DC-SIGN binds glycans containing high mannose
structures appear not to be present in the published structure of
the serotype 2 capsular polysaccharide [46]. However, it is possible
that the involvement of other C –type lectin receptors on DC or
other glycan structures may be involved in the immunomodulatory
effects of the SS2 capsule.
Over a period of 5 hours after internalization in DC the
number of viable S. suis were reduced about 100 fold. The rate of
killing and overall levels of intracellular survival of S. suis after
5 hours was higher than that reported previously using porcine
DC [25]. This may have been due the use of a different serotype 2
strain and/or differences in killing capacity of human and pig DCs
and warrants further study. Despite the fact that a high proportion
of phagocytized S. suis were killed by DC in the first 5 hours of
incubation we were able to recover around 10
3 CFU of SS2 and
the unencapsulated mutant after 24 hours incubation (Fig. 4B). In
these experiments antibiotics were added to the medium for
5 hours to kill extracellular and adhered bacteria then the medium
was replaced by RPMI without antibiotics, to prevent the
antibiotics from entering the DCs. Prior to lysis antibiotics were
added a second time to some of the samples to kill any
extracellular bacteria that might have been released from DC.
The results (Fig. 4B) showed that the CFU counts present after
24 hour could indeed be attributed to the presence of viable
intracellular S. suis. This has important consequences for
pathogenesis because activated DCs eventually undergo apoptosis
and may release viable S. suis. As DC traffic from the mucosa
travel via the bloodstream to lymphoid tissue such a mechanism
may enable S. suis to rapidly disseminate in the body during
invasive disease.
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